News on mass spectrometry technology and applications in genetics, genomics, and molecular diagnostics.
The Finnish diagnostics company is working to expand US and European sales of its ceramide lipid-based cardiovascular risk assessment assay, CERT.
The study is part of a broader effort by academic and industry researchers to develop blood-based tests for easier, less expensive Alzheimer's screening.
The ongoing opioid epidemic has heightened demand among physicians for more frequent and more rapid drug testing.
Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.
The researchers are developing immuno-selected-reaction monitoring (SRM) mass spec to measure proteins linked to various immunodeficiency disorders.
